Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.

Ebola viruses (EBOV) can cause severe hemorrhagic disease with high case fatality rates. Currently, no vaccines or therapeutics are approved for use in humans. Ebola virus-like particles (eVLP) comprising of virus protein (VP40), glycoprotein, and nucleoprotein protect rodents and nonhuman primates from lethal EBOV infection, representing as a candidate vaccine for EBOV infection. Previous reports have shown that eVLP stimulate the expression of proinflammatory cytokines in dendritic cells (DCs) and macrophages (MΦs) in vitro. However, the molecular mechanisms and signaling pathways through which eVLP induce innate immune responses remain obscure. In this study, we show that eVLP stimulate not only the expression of proinflammatory cytokines but also the expression of type I interferons (IFNs) and IFN-stimulated genes (ISGs) in murine bone marrow-derived DCs (BMDCs) and MΦs. Our data indicate that eVLP trigger host responses through toll-like receptor (TLR) pathway utilizing 2 distinct adaptors, MyD88 and TRIF. More interestingly, eVLP activated the IFN signaling pathway by inducing a set of potent antiviral ISGs. Last, eVLP and synthetic adjuvants, Poly I:C and CpG DNA, cooperatively increased the expression of cytokines and ISGs. Further supporting this synergy, eVLP when administered together with Poly I:C conferred mice enhanced protection against EBOV infection. These results indicate that eVLP stimulate early innate immune responses through TLR and type I IFN signaling pathways to protect the host from EBOV infection.

[1]  Steven B. Bradfute,et al.  Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection , 2015, PloS one.

[2]  J. Dye,et al.  A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge , 2011, Proceedings of the National Academy of Sciences.

[3]  R. Steinman,et al.  Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans , 2011, The Journal of experimental medicine.

[4]  M. Aman,et al.  Advances in virus-like particle vaccines for filoviruses. , 2011, The Journal of infectious diseases.

[5]  Steven B. Bradfute,et al.  Filovirus infection of STAT-1 knockout mice. , 2011, The Journal of infectious diseases.

[6]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[7]  Christopher T. Jones,et al.  A diverse array of gene products are effectors of the type I interferon antiviral response , 2011, Nature.

[8]  S. Akira,et al.  Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.

[9]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[10]  M. Colonna,et al.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance , 2010, Immunological reviews.

[11]  Atsushi Okumura,et al.  Interaction between Ebola Virus Glycoprotein and Host Toll-Like Receptor 4 Leads to Induction of Proinflammatory Cytokines and SOCS1 , 2009, Journal of Virology.

[12]  R. Steinman,et al.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant , 2009, The Journal of experimental medicine.

[13]  Steven B. Bradfute,et al.  Ebola Zaire Virus Blocks Type I Interferon Production by Exploiting the Host SUMO Modification Machinery , 2009, PLoS pathogens.

[14]  P. Bates,et al.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein , 2009, Proceedings of the National Academy of Sciences.

[15]  B. Beutler.  TLRs and innate immunity. , 2009, Blood.

[16]  Xiaoyu Hu,et al.  Regulation of interferon and Toll‐like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms , 2008, Immunological reviews.

[17]  Paolo Ascenzi,et al.  Ebolavirus and Marburgvirus: insight the Filoviridae family. , 2008, Molecular aspects of medicine.

[18]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[19]  M. Bray,et al.  Filovirus research: knowledge expands to meet a growing threat. , 2007, The Journal of infectious diseases.

[20]  Y. Kawaoka,et al.  Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. , 2007, The Journal of infectious diseases.

[21]  B. Pulendran,et al.  The science of adjuvants , 2007, Expert review of vaccines.

[22]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[23]  Lucia Gabriele,et al.  The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. , 2007, Immunity.

[24]  C. Basler,et al.  Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. , 2007, Virology.

[25]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[26]  A. Bowie,et al.  The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling , 2007, Nature Reviews Immunology.

[27]  R. Medzhitov,et al.  Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. , 2007, Current opinion in immunology.

[28]  A. Bagchi,et al.  MyD88-Dependent and MyD88-Independent Pathways in Synergy, Priming, and Tolerance between TLR Agonists1 , 2007, The Journal of Immunology.

[29]  K. Mossman,et al.  The IFN-Independent Response to Virus Particle Entry Provides a First Line of Antiviral Defense That Is Independent of TLRs and Retinoic Acid-Inducible Gene I1 , 2006, The Journal of Immunology.

[30]  Edgar Schmitt,et al.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.

[31]  R. N. Harty,et al.  Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology , 2006, Virology Journal.

[32]  G. Trinchieri,et al.  Production of type I interferons , 2005, The Journal of experimental medicine.

[33]  M. Bray,et al.  Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. , 2005, The international journal of biochemistry & cell biology.

[34]  D. Swenson,et al.  Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection1 , 2005, The Journal of Immunology.

[35]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[36]  A. Dunne,et al.  Adaptor usage and Toll‐like receptor signaling specificity , 2005, FEBS letters.

[37]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[38]  Hideo Negishi,et al.  IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.

[39]  J. O’Shea,et al.  IFN Regulatory Factor-4 and -8 Govern Dendritic Cell Subset Development and Their Functional Diversity , 2005, The Journal of Immunology.

[40]  B. Beutler,et al.  Identification of a TLR4‐ and TRIF‐dependent activation program of dendritic cells , 2004, European journal of immunology.

[41]  M. Mohamadzadeh,et al.  Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Ruthel,et al.  Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. , 2003, The Journal of infectious diseases.

[43]  Heinz Feldmann,et al.  Ebola virus: from discovery to vaccine , 2003, Nature Reviews Immunology.

[44]  R. Ahmed,et al.  Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. , 2003, Virology.

[45]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[46]  C. Bode,et al.  CpG DNA as a vaccine adjuvant , 2003, Expert review of vaccines.

[47]  E. Fish,et al.  Review: IFN-α/β Receptor Interactions to Biologic Outcomes: Understanding the Circuitry , 2002 .

[48]  Emiko Suzuki,et al.  Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP , 2002, Journal of Virology.

[49]  A. B. Will,et al.  Lipid Raft Microdomains , 2002, The Journal of experimental medicine.

[50]  M. Colonna,et al.  Virus-induced Interferon α Production by a Dendritic Cell Subset in the Absence of Feedback Signaling In Vivo , 2002, The Journal of experimental medicine.

[51]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[52]  S. Akira,et al.  Unresponsiveness of MyD88-deficient mice to endotoxin. , 1999, Immunity.

[53]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.

[54]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[55]  W. Fellows-Mayle,et al.  Journal of Translational Medicine Toll like Receptor-3 Ligand Poly-iclc Promotes the Efficacy of Peripheral Vaccinations with Tumor Antigen-derived Peptide Epitopes in Murine Cns Tumor Models , 2022 .